DK4176877T3 - Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom - Google Patents

Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom Download PDF

Info

Publication number
DK4176877T3
DK4176877T3 DK22194251.9T DK22194251T DK4176877T3 DK 4176877 T3 DK4176877 T3 DK 4176877T3 DK 22194251 T DK22194251 T DK 22194251T DK 4176877 T3 DK4176877 T3 DK 4176877T3
Authority
DK
Denmark
Prior art keywords
patients
improving
methods
cardiac function
fabrys
Prior art date
Application number
DK22194251.9T
Other languages
English (en)
Inventor
Jeff Castelli
Jay Barth
Nina Skuban
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4176877(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK4176877T3 publication Critical patent/DK4176877T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK22194251.9T 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom DK4176877T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
EP18766482.6A EP3675853B1 (en) 2017-08-28 2018-08-28 Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease

Publications (1)

Publication Number Publication Date
DK4176877T3 true DK4176877T3 (da) 2025-02-24

Family

ID=63528948

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18766482.6T DK3675853T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom
DK22194251.9T DK4176877T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18766482.6T DK3675853T3 (da) 2017-08-28 2018-08-28 Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom

Country Status (26)

Country Link
US (1) US20200222377A1 (da)
EP (3) EP3675853B1 (da)
JP (3) JP7755929B2 (da)
KR (2) KR20250049561A (da)
CN (1) CN111770753A (da)
AR (1) AR112482A1 (da)
AU (2) AU2018326364B2 (da)
CA (1) CA3074450C (da)
CL (1) CL2020000491A1 (da)
DK (2) DK3675853T3 (da)
EA (1) EA202090564A1 (da)
ES (2) ES2931054T3 (da)
FI (1) FI4176877T3 (da)
HR (2) HRP20250064T1 (da)
HU (2) HUE060287T2 (da)
IL (3) IL272893B2 (da)
LT (2) LT3675853T (da)
MX (2) MX2020002229A (da)
PL (2) PL4176877T3 (da)
PT (2) PT3675853T (da)
RS (2) RS66515B1 (da)
SG (1) SG11202001707PA (da)
SI (1) SI4176877T1 (da)
SM (2) SMT202500073T1 (da)
TW (1) TWI845479B (da)
WO (1) WO2019046244A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
US20200222377A1 (en) 2017-08-28 2020-07-16 Amicus Therapeutics, Inc. Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US12594268B2 (en) 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) * 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US20200222377A1 (en) 2017-08-28 2020-07-16 Amicus Therapeutics, Inc. Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
EP3676914B1 (en) 2017-08-28 2023-08-16 John Mezzalingua Associates LLC Weather protecting (wp) housing for coaxial cable connectors

Also Published As

Publication number Publication date
US20200222377A1 (en) 2020-07-16
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
CA3074450C (en) 2024-10-01
JP2020531550A (ja) 2020-11-05
AR112482A1 (es) 2019-10-30
SG11202001707PA (en) 2020-03-30
RS63742B1 (sr) 2022-12-30
ES3013820T3 (en) 2025-04-15
AU2018326364B2 (en) 2024-08-29
IL272893A (en) 2020-04-30
CN111770753A (zh) 2020-10-13
EP4176877A1 (en) 2023-05-10
AU2018326364A1 (en) 2020-04-09
IL272893B2 (en) 2024-07-01
DK3675853T3 (da) 2022-11-28
FI4176877T3 (fi) 2025-03-06
LT4176877T (lt) 2025-02-10
HUE070433T2 (hu) 2025-06-28
EP4176877B1 (en) 2024-12-04
MX2020002229A (es) 2020-07-20
IL310648A (en) 2024-04-01
LT3675853T (lt) 2022-12-12
KR20200044908A (ko) 2020-04-29
TWI845479B (zh) 2024-06-21
BR112020003974A2 (pt) 2020-09-01
CL2020000491A1 (es) 2020-09-11
KR102790184B1 (ko) 2025-04-01
CA3074450A1 (en) 2019-03-07
PT3675853T (pt) 2022-11-28
WO2019046244A1 (en) 2019-03-07
HUE060287T2 (hu) 2023-02-28
AU2024266945A1 (en) 2024-12-19
JP2025138638A (ja) 2025-09-25
HRP20221366T1 (hr) 2023-01-06
IL272893B1 (en) 2024-03-01
JP2023051998A (ja) 2023-04-11
EP3675853A1 (en) 2020-07-08
HRP20250064T1 (hr) 2025-03-14
SI4176877T1 (sl) 2025-03-31
EA202090564A1 (ru) 2020-06-15
KR20250049561A (ko) 2025-04-11
RS66515B1 (sr) 2025-03-31
PL3675853T3 (pl) 2022-12-27
EP4588476A1 (en) 2025-07-23
PT4176877T (pt) 2025-02-24
IL324182A (en) 2025-12-01
JP7755929B2 (ja) 2025-10-17
EP3675853B1 (en) 2022-09-07
SMT202200459T1 (it) 2023-01-13
TW201919619A (zh) 2019-06-01
PL4176877T3 (pl) 2025-04-07
ES2931054T3 (es) 2022-12-23

Similar Documents

Publication Publication Date Title
DK4176877T3 (da) Fremgangsmåder til forbedring og/eller stabilisering af hjertefunktionen hos patienter med fabrys sygdom
DK3694529T3 (da) Trispecifikke proteiner og anvendelsesfremgangsmåder
IL289099A (en) Methods for the storage of whole blood, and compositions thereof
IL262831A (en) Medical implants and methods of preparation thereof
DK3781034T3 (da) Laktatsensorer og tilhørende fremgangsmåder
DK3676285T3 (da) Vaccine til anvendelse i profylakse og/eller behandling af en sygdom
DK3319611T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3141199T3 (da) Medicinsk mikrorobot og mikrorobotsystem med samme
DK3265043T3 (da) Hjælpemiddel til patienttransport og -træning
DK3233130T3 (da) Nukleinsyrekonstruktioner og genterapivektorer til anvendelse i behandlingen af wilson-sygdom
DK3436022T3 (da) Oxysteroler og fremgangsmåder til anvendelse heraf
DK3319612T3 (da) Oxysteroler og fremgansmåder til anvendelse derfor
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
DK3247352T3 (da) Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion
IL281504A (en) Methods and kits for preparing pathogen-inactivated whole blood
DK3356444T3 (da) Med silikoneharpiks modificerede isocyanatoalkylalkoxysilan-addukter og deres anvendelse
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3364915T3 (da) Medicinsk indretning til registrering og/eller stimulering af væv
EP3445431A4 (en) PATIENT INTERFACE AND ASPECTS THEREOF
EP3585260C0 (en) SENSOR CONFIGURATION IN A MEDICAL MAGNETOMETER
DK3387019T3 (da) Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
DK2810624T3 (da) Pude til behandling og/eller forebyggelse af kraniedeformiteter hos spædbørn.
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
DK3641795T3 (da) Methods and materials for treating blood vessels